Novartis AG (NVSEF)
| Market Cap | 276.38B |
| Revenue (ttm) | 56.37B |
| Net Income (ttm) | 14.39B |
| Shares Out | n/a |
| EPS (ttm) | 7.30 |
| PE Ratio | 19.20 |
| Forward PE | 16.50 |
| Dividend | 3.97 (2.89%) |
| Ex-Dividend Date | Mar 11, 2025 |
| Volume | 1,569 |
| Average Volume | 17,376 |
| Open | 143.88 |
| Previous Close | 147.09 |
| Day's Range | 138.06 - 146.15 |
| 52-Week Range | 96.93 - 149.80 |
| Beta | 0.45 |
| RSI | 54.86 |
| Earnings Date | Feb 4, 2026 |
About Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocy... [Read more]
Financial Performance
In 2024, Novartis AG's revenue was $51.72 billion, an increase of 10.85% compared to the previous year's $46.66 billion. Earnings were $11.94 billion, a decrease of -19.59%.
Financial StatementsNews
FDA Grants Novartis Breakthrough Therapy Status To Ianalumab For Sjögren's Disease
(RTTNews) - Novartis announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to ianalumab for Sjögren's disease, the second most prevalent rheumatic autoimmun...
Novartis (NVS) Gains FDA Breakthrough Status for Sjögren's Disease Therapy
Novartis (NVS) Gains FDA Breakthrough Status for Sjögren's Disease Therapy
Novartis wins FDA breakthrough status for Sjögren’s disease therapy
Novartis (NVS) Gains FDA Breakthrough Status for Sjogren's Disease Drug
Novartis (NVS) Gains FDA Breakthrough Status for Sjogren's Disease Drug
Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsight
New York, USA, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Generalized Myasthenia Gravis Market Outlook Shows Strong Momentum During the Forecast Period (2025–2034) Driven by Novel Immunotherapies | DelveInsigh...
Novartis CEO Dr. Vasant Narasimhan sits down with Jim Cramer
Novartis CEO Dr. Vasant Narasimhan joins 'Mad Money' host Jim Cramer to talk its product pipeline, vaccine development, utilizing AI, and more.
Novartis (NVS) Secures License for Peptide-Based Radioligand Therapy
Novartis (NVS) Secures License for Peptide-Based Radioligand Therapy
Zonsen PepLib Biotech and Novartis Sign Worldwide License Agreement regarding Radioligand Therapy Asset
ZHUZHOU, China & BOSTON--(BUSINESS WIRE)--Zonsen PepLib Biotech Inc. (“PepLib”) today announced that it has entered into a worldwide license agreement with Novartis for an undisclosed peptide-based as...
China’s SciNeuro, Novartis sign US$1.7 billion licensing deal to develop Alzheimer’s drugs
A partnership between China’s SciNeuro Pharmaceuticals and Swiss pharmaceutical giant Novartis on Monday has revived hopes for treating Alzheimer’s disease. The deal, worth nearly US$1.7 billion, gran...
Novartis AG at JPMorgan Healthcare Conference Transcript
Novartis AG at JPMorgan Healthcare Conference Transcript
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
2026-01-12. The following slide deck was published by Novartis AG in conjunction with this event.
Novartis AG (NVS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novartis eyes more bolt-on acquisitions, CEO says
Novartis will continue to do bolt-on deals and its capital allocation priorities remain unchanged, CEO Vasant Narasimhan said at a major industry conference that kicked off on Monday in San Francisco.
Is Novartis AG Gaining or Losing Market Support?
Novartis AG's (NYSE: NVS) short interest as a percent of float has risen 7.69% since its last report. According to exchange reported data, there are now 5.42 million shares sold short , which is 0.28...
SciNeuro, Novartis sign $1.7 billion licensing deal to develop Alzheimer's drugs
Swiss drugmaker Novartis has signed a licensing deal worth nearly $1.7 billion with privately held SciNeuro Pharmaceuticals to develop potential antibody treatments for Alzheimer's disease, the biotec...
Deal St: Cognizant inks over $1bn contract with Novartis
India News: BENGALURU: Cognizant is learnt to have secured a deal worth over $1 billion from Swiss pharma major Novartis as part of a consolidation contract that .
3 Dividend Stocks to Buy in 2026 and Hold Forever
Visa and Novartis have strong dividend track records and attractive long-term outlooks. Meta Platforms initiated a dividend two years ago, adding appeal to its already strong growth prospects.
Novartis (NVS) Expands U.S. Radioligand Therapy Manufacturing with New Facility
Novartis (NVS) Expands U.S. Radioligand Therapy Manufacturing with New Facility
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
East Hanover, N.J., January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter P...
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Basel, January 9, 2026 – Novartis, a leading global innovative medicines company, today announced plans to build its fourth US radioligand therapy (RLT) manufacturing facility in Winter Park, Florida....
New Investors: 3 Stocks to Build Your Portfolio Around in 2026
Novartis, Home Depot, and American Express are well-known, blue chip stocks They have all generated strong gains in recent years and have excellent fundamentals. All three can be suitable building blo...
Barclays Upgrades Novartis (NVS) Rating to Equal-Weight | NVS Stock News
Barclays Upgrades Novartis (NVS) Rating to Equal-Weight | NVS Stock News
Exclusive: Drugmakers raise US prices on 350 medicines despite pressure from Trump
Drugmakers plan to raise U.S. prices on at least 350 branded medications including vaccines against COVID, RSV and shingles and blockbuster cancer treatment Ibrance, even as the Trump administration p...
Novartis: A Mispriced Hedge In A Crowded Equity Market
2 Top Stocks to Buy and Hold for the Long Term
Novartis has proved that it can navigate headwinds such as patent cliffs and a slow economy. Shopify's long-term ambitions are off to a great start, given its large addressable market and economic moa...